论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
乌司他丁治疗COVID-19的疗效:一项回顾性研究
Received 26 August 2024
Accepted for publication 3 December 2024
Published 24 December 2024 Volume 2024:17 Pages 6421—6430
DOI https://doi.org/10.2147/IJGM.S486434
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Sandul Yasobant
Peng Liu,1,2 Qi Wu,3 Mengjie Li2
1School of Graduate, Tianjin Medical University, Tianjin, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, Cangzhou Fifth Hospital (People’s Hospital of Qingxian), Cangzhou, People’s Republic of China; 3Department of Respiratory Medicine, General Hospital of Tianjin Medical University, Tianjin, People’s Republic of China
Correspondence: Qi Wu, Department of Respiratory Medicine, General Hospital of Tianjin Medical University, Tianjin, People’s Republic of China, Email wuqitjykdxzyy@163.com
Purpose: This retrospective study aimed to evaluate the efficacy of ulinastatin in the treatment of COVID-19 patients compared to conventional therapy.
Patients and Methods: A total of 437 COVID-19 patients admitted to the Respiratory Oncology Department of our hospital between December 31, 2022, and July 8, 2023, were included in the study. Patients were classified into the observation group (n=62) receiving ulinastatin in addition to standard treatment and the control group (n=347) receiving standard treatment only. Clinical information, laboratory results, and treatment outcomes were collected and analyzed.
Results: The observation group showed an improvement in lymphocyte count compared to the control group. The clinical improvement rate in patients receiving ulinastatin for 7 days or longer was 92.1%, significantly higher than that of patients treated for less than 7 days (62.5%) and those receiving standard treatment (71.0%). No significant difference in total length of hospitalization was observed between the two groups, and no related adverse events occurred in either group.
Conclusion: Ulinastatin treatment improves lymphocyte counts in severe COVID-19 patients, and the clinical improvement rate is significantly higher with treatment duration of 7 days or longer. Larger-scale randomized controlled trials are warranted to further explore the role of ulinastatin in the management of COVID-19.
Keywords: COVID-19, ulinastatin, severe cases, clinical improvement, radiographic findings